---
provider: claude_code
model: claude-haiku-5-5, claude-sonnet-5-5
cached: false
start_time: '2026-10-30T04:40:08.969833'
end_time: '2026-10-30T04:41:09.458314'
duration_seconds: 60.49
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: MOS-related Oocyte Zygote Embryo Maturation Arrest
  mondo_id: MONDO:0957278
  category: Mendelian
  causal_genes: MOS
  omim_id: OMIM:620383
  synonyms: OZEMA20; MOS-related female infertility; MOS-related early embryonic arrest
    and fragmentation
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-haiku-5-5
  - claude-sonnet-5-5
  web_search_requests: 4
  num_turns: 5
  total_cost_usd: 0.8255065
  session_id: 7cf4d4d2-202c-5e35-b74d-6f65c6e8bfd8
  stop_reason: end_turn
  assistant_text_blocks: 1
citation_count: 7
reference_validation:
  total_references: 3
  verified: 1
  not_found: 0
  unverifiable: 2
  confabulation_rate: 0.0
  relevance_assessed: 1
  on_topic: 1
  validator_version: 0.4.0
term_validation:
  total_terms: 9
  verified: 8
  not_found: 0
  obsolete: 0
  unverifiable: 1
  confabulation_rate: 0.0
  labels_checked: 1
  labels_matching: 1
  unresolvable_prefixes:
  - OMIM
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** MOS-related Oocyte Zygote Embryo Maturation Arrest
- **MONDO ID:** MONDO:0957278 (if available)
- **Causal gene(s):** MOS
- **OMIM:** OMIM:620383
- **Synonyms:** OZEMA20; MOS-related female infertility; MOS-related early embryonic arrest and fragmentation
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **MOS-related Oocyte Zygote Embryo Maturation Arrest** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# MOS-related Oocyte/Zygote/Embryo Maturation Arrest (OZEMA20): research report

**Scope and verification.** I ran three web searches and read only the search summaries, not the full texts. Statements from those results are linked. Other statements come from background knowledge and are marked **[unverified]**. I give no PMIDs because I could not confirm any. The DOI and PMC links below came from the search results. Quotes are paraphrases of search summaries, not verified abstract text, and need exact-snippet checking with `just fetch-reference` before use as evidence.

The causal gene is **MOS** (MOS proto-oncogene, serine/threonine kinase, hgnc:7199 **[unverified, look up before binding]**; UniProt P00540). The disease is OMIM:620383, "Oocyte/zygote/embryo maturation arrest 20" (OZEMA20). The MONDO ID MONDO:0957278 was given in the brief and I did not confirm it.

---

## 1. Disease information

- OZEMA20 is an autosomal recessive female infertility disorder. Biallelic MOS variants cause early embryonic arrest and fragmentation (EEAF) after fertilization. The oocyte retrieves and fertilizes, but embryos stop in the cleavage stages and fragment ([UniProt/OMIM summary via search](https://uniprot.org/uniprotkb/P00540); [Zhang et al. 2021, PMC8649871](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649871/)).
- **Naming caveat.** "Maturation arrest" in the OZEMA series covers oocyte maturation arrest, zygote arrest and embryo arrest as a family. The reported MOS phenotype is mainly **early embryonic arrest with fragmentation**, not a classic germinal-vesicle or MI oocyte arrest. The searches did not show the full OMIM clinical synopsis, so I could not check the OMIM text.
- KEGG lists the parent entity at [H01897](https://www.kegg.jp/entry/H01897). [PanelApp Australia](https://panelapp-aus.org/panels/4455/gene/MOS/) lists MOS with biallelic inheritance and a green rating.
- Synonyms from the brief: OZEMA20; MOS-related female infertility; MOS-related early embryonic arrest and fragmentation. Orphanet, ICD-11 and MeSH identifiers were not checked.
- The data come from aggregated research cohorts of IVF patients with exome sequencing. They do not come from EHR.

## 2. Etiology

- **Cause.** Biallelic loss-of-function or hypomorphic MOS variants in the woman. Zhang et al. 2021 reported four rare variants in three infertile women with recessive inheritance. The variants were homozygous c.285C>A (p.Asn95Lys), homozygous c.960C>A (p.Cys320Ter), and compound heterozygous c.416T>C (p.Met139Thr) with c.737G>A (p.Arg246His) ([Zhang 2021](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649871/)). Zeng et al. 2022 (Hum Reprod) added two families, with p.Asn95Lys and c.467delG (p.Gly156Alafs*18) ([OUP](https://academic.oup.com/humrep/article/37/3/612/6498326)). The searches also surfaced a companion paper, ["MOS is a novel genetic marker for human early embryonic arrest and fragmentation"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649885/), which I did not read.
- **Risk and protective factors.** None are documented. No environmental, lifestyle or gene-environment contribution is known. No modifier genes or protective alleles have been reported.

## 3. Phenotypes

Evidence comes from small case series (about 5 families), so frequencies are not available. Suggested HPO terms need lookup before binding.

| Phenotype | Suggested HPO (verify) | Comment |
|---|---|---|
| Female infertility | HP:0008222 | Primary infertility |
| Recurrent failed IVF/ICSI cycles | HP:0034210? | Check for a better term |
| Early embryonic arrest / fragmentation | no precise term likely | Possibly a coarse binding with `NO_HPO_TERM` |
| Abnormal oocyte morphology or maturation | check the HPO "Abnormal oocyte" subtree | |

Reported in the summaries: oocytes retrieved and fertilized, with cleavage-stage embryos that arrest and fragment. The summary of the MGI entry mentions amenorrhea as an additional feature in some databases, but I could not verify it. No systemic phenotype is reported. Onset is at the first reproductive attempt. Quality-of-life impact is not studied.

## 4. Genetic and molecular information

- **Gene and protein.** MOS encodes a serine/threonine kinase (c-Mos, cytostatic factor component) that phosphorylates MEK1 and thereby activates ERK1/2 (MAPK). It is expressed in oocytes.
- **Variant types.** Missense (p.Asn95Lys, p.Met139Thr, p.Arg246His), nonsense (p.Cys320Ter) and frameshift (p.Gly156Alafs*18). All are germline.
- **Functional consequences.** Loss of function. Zeng et al. reported that p.Asn95Lys and the frameshift reduced MOS protein level and that all tested variants reduced the ability of MOS to phosphorylate its downstream target ([OUP](https://academic.oup.com/humrep/article/37/3/612/6498326)). Zhang et al. reported reduced ERK1/2 activation ([Zhang 2021](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649871/)).
- The `functional_impact_category` is `LOSS_OF_FUNCTION` or `PARTIAL_LOSS_OF_FUNCTION`, to be assigned per variant.
- gnomAD frequencies and ClinVar classifications were not checked. No ClinGen gene-disease validity record was checked, so run `just check-gene-validity`. Epigenetic, chromosomal and modifier-gene data are not available.

## 5. Environmental information

None are reported. There are no infectious agents.

## 6. Mechanism and pathophysiology

**Causal chain** (steps 1–5 are demonstrated in human variant assays and cell assays; the later links are partly inferred):

1. Biallelic germline MOS variants reduce MOS protein level or kinase activity (human variant assays, [Zeng 2022](https://academic.oup.com/humrep/article/37/3/612/6498326)).
2. This leads to reduced MEK–ERK1/2 phosphorylation in the oocyte (human variant assays, [Zhang 2021](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649871/)).
3. This results in defective oocyte cytoplasmic maturation, with impaired meiotic resumption and cytoskeleton assembly defects (described in the search summary; the specific human evidence is not verified).
4. Maternal mRNA clearance fails during maturation. This was shown in human MII oocytes carrying the MOS variant and in oocytes treated with the MEK inhibitor U0126. The affected transcripts were linked to mitochondrial function ([EMBO Mol Med 2021, DOI](https://doi.org/10.15252/emmm.202114887)).
5. Defective maternal-to-zygotic transition follows, which is inferred. The embryo then arrests at the cleavage stage and fragments.
6. The clinical result is infertility.

**Branch from mouse biology.** In the mouse, Mos-null oocytes fail to maintain metaphase II arrest, with spindle abnormalities, a large polar body and parthenogenetic activation. Oocyte-specific Erk1/2 knockout mice reproduce the human EEAF phenotype ([search summary](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649871/)). The human phenotype is therefore not a simple MII-arrest failure. The human oocytes of these patients mature to MII and fertilize, so the MII-arrest role in humans is unresolved.

**Ontology suggestions (verify each by lookup).** GO terms: MAPK cascade (GO:0000165), oocyte maturation (GO:0001556), MAP kinase kinase kinase activity, regulation of mRNA stability, and cytoplasmic mRNA processing. Cell types: oocyte (CL:0000023), zygote (CL:0000365), early embryo blastomere. Anatomy: ovary and embryo.

## 7. Anatomical structures affected

The ovary (follicle and oocyte) and the preimplantation embryo. The cell types are the oocyte and the cleavage-stage blastomeres. At the subcellular level, the meiotic spindle and cytoskeleton, the cytoplasmic maternal mRNA pool and the mitochondria are affected. The disease is bilateral, with no other organ involved.

## 8. Temporal development

The condition is congenital genetically but becomes apparent in adulthood, at the first IVF cycle. It is non-progressive and persistent, with no spontaneous remission reported. The critical period is oocyte maturation through the early cleavage stages.

## 9. Inheritance and population

- Autosomal recessive. Both a homozygous and a compound heterozygous genotype are described.
- Only women are affected clinically. Male carriers are fertile **[unverified]**.
- Prevalence is unknown. About 5 families are known. Zhang 2021 and Zeng 2022 cohorts are East Asian (Chinese), but I did not verify the ancestry. Founder effect and consanguinity were not checked. The source search summaries do not report them.

## 10. Diagnostics

- Genetic testing by exome sequencing or a female-infertility or embryo-arrest gene panel, followed by segregation analysis. MOS is on [PanelApp's panel 4455](https://panelapp-aus.org/panels/4455/gene/MOS/).
- Functional confirmation is possible in research settings by testing phospho-ERK1/2 in patient oocytes or in HEK293 cells expressing the variant.
- Clinical clues are recurrent EEAF despite normal fertilization and normal semen parameters.
- The differential diagnosis includes other genes for embryo arrest (PADI6, TLE6, NLRP5, KHDC3L, PABPC1L, WEE2 for fertilization failure) and non-genetic causes such as sperm factors and culture conditions. Cascade screening of sisters and prenatal or preimplantation testing apply.

## 11. Outcome and prognosis

Life expectancy is normal. The morbidity is infertility and the psychosocial burden of repeated failed IVF cycles. Spontaneous pregnancy has not been reported. No prognostic factors are known.

## 12. Treatment

- No disease-modifying treatment exists. Repeated conventional IVF/ICSI with the patient's own oocytes does not overcome the arrest.
- **Practical option: oocyte donation.** This is standard for genetically determined oocyte-intrinsic arrest **[unverified for MOS specifically]**.
- **Experimental: not clinically tested.** Possible approaches include ooplasm or mRNA rescue, as the search summary on mechanism suggests; I found no human trial. I found no registered trial (ClinicalTrials.gov not searched).
- **NCIT suggestions (verify by lookup):** assisted reproductive technology / in vitro fertilization, oocyte donation, genetic counseling (`NCIT:C15240`, listed in the repo guide). Do not infer a `therapeutic_modality` for these.

## 13. Prevention

Genetic counseling is the main measure. Carrier testing of at-risk relatives and preimplantation genetic testing for the family variants are possible in principle, though PGT is of limited value when the affected woman's own oocytes arrest. There is no primary prevention.

## 14. Other species and natural disease

Orthologs exist across vertebrates. Mos is a classic cytostatic factor in *Xenopus*. No natural veterinary disease was checked (OMIA not searched).

## 15. Model organisms

- **Mouse Mos knockout.** Females are viable and sterile. Oocytes reach MII but fail to maintain arrest, with spindle abnormalities and parthenogenetic activation. Early reports are Colledge et al. and Hashimoto et al. 1994 (Nature) **[unverified, citations not looked up]**. The mouse phenotype only partly matches the human one.
- **Oocyte-specific Erk1/2 knockout mouse.** Reproduces the human EEAF phenotype ([Zhang 2021](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649871/)). It is the better model of the human mechanism and should be linked with `PARTIALLY_RECAPITULATES` or `RECAPITULATES`, with a divergence note.
- **In vitro.** U0126 inhibitor treatment of human oocytes and cell-line assays of the variants. These are `IN_VITRO` evidence.
- The `HUMAN_MODEL_MISMATCH` discussion kind applies to the MII-arrest difference.

## Curation notes and gaps

- Fetch and cache the two primary papers ([Zhang 2021](https://doi.org/10.15252/emmm.202114887), [Zeng 2022](https://academic.oup.com/humrep/article/37/3/612/6498326)) and the companion paper above with `just fetch-reference`. Take exact snippets only from the cached bodies.
- Look up every CURIE (hgnc, HP, GO, CL, UBERON, NCIT) before binding. Run `just check-gene-validity` and the GeneReviews check. I found no GeneReviews chapter.
- Open questions: the true prevalence, the reason human oocytes mature despite loss of MOS, whether more families exist after 2022, and whether any rescue strategy works.

## Sources

- [Zhang et al. 2021, EMBO Mol Med (PMC8649871)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649871/)
- [Companion paper (PMC8649885)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649885/)
- [Zeng et al. 2022, Hum Reprod](https://academic.oup.com/humrep/article/37/3/612/6498326)
- [EMBO Mol Med DOI](https://doi.org/10.15252/emmm.202114887)
- [UniProt P00540](https://uniprot.org/uniprotkb/P00540)
- [PanelApp Australia, panel 4455](https://panelapp-aus.org/panels/4455/gene/MOS/)
- [KEGG H01897](https://www.kegg.jp/entry/H01897)

## Reference Validation

Checked with `linkml-reference-validator` 0.4.0.

| Outcome | Count |
| --- | --- |
| References checked | 3 |
| Resolved | 1 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 2 |
| References weighed for topical relevance | 1 |
| On topic | 1 |
| Off topic | 0 |

1 of 3 references resolved; the rest could not be looked up either way.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 9 |
| Resolved | 8 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 1 |
| Terms whose name was checked | 1 |
| Terms named correctly | 1 |
| Terms named as a **different** term | 0 |

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `OMIM`.

8 of 9 terms resolved to a current term; the rest could not be looked up either way.